head and neck cancer
Conditions
Interventions
standard of care
start gabapentin on the first day of radiation therapy
Sponsors
Kobe University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. PS (ECOG): 0-2 2. Histologically diagnosed malignant tumor 3. Primary site: oral cavity, nasopharynx, oropharynx, hypopharyns, larynx 4. Head and neck cancer patients who are to be treated with radiation or chemoradiation therapy 5. Dose of radiation: more than 60Gy 6. Patients provided written informed consent 7. Chemothrapy: cisplatin or cisplatin+fluorouracil
Exclusion criteria
Exclusion criteria: 1. malignant tumors of other organs 2. women who are pregnant or breast feeding 3. with mental disorder 4. recieve the systemic therapy of steroid continuously 5. inadequately controlled diabetes 6. have the history of miocardial or cerebral infarction within 3 months 7. with sever active co-mobidity (COPD, interstitial pneumonitis, angina pectoris and so on) 8. a previous history of a severe drug hypersensitivity against an anticonvulsant agent 9. moderate and severe renal dysfunction (creatinine clearance<60mL/min.), severe liver dysfunction (T-Bil>2.0mg/dL) 10. severe infection with systemic aaministration 11. use of anticonvulsant or antidepressant drug 12. use of pain killer before starting radiation therapy 13. visual analogue scale (VAS): over 4.0 before starting radiation therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The maximum of visual analogue scale (VAS) during the treatment | — |
Countries
Japan
Contacts
Public ContactTomoko Kataoka
Kobe University Hospital Oral and Maxillofacial Surgery
Outcome results
None listed